1,5-Dimethyl-4-hydroxymethylpyrazole | 103946-58-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1,5-Dimethyl-4-hydroxymethylpyrazole
• 英文别名: (1,5-dimethyl-1H-pyrazol-4-yl)methanol；(1,5-dimethylpyrazol-4-yl)methanol
• CAS: 103946-58-3
• 化学式: C₆H₁₀N₂O
• mdl: MFCD02253731
• 分子量: 126.158
• InChiKey: ZLKFGFIBRVAIDL-UHFFFAOYSA-N

物化性质

• 沸点：
  252.9±25.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933199090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  1,5-Dimethyl-4-hydroxymethylpyrazole 在 溴 、 sodium hydroxide 作用下， 以 水 为溶剂， 以65%的产率得到4-溴-1,5-二甲基-1H-吡唑
  参考文献：
  名称：

  Bromination of 1,3-dimethyl- and 1,5-dimethyl-4-hydroxymethylpyrazoles

  摘要：

  DOI：

  10.1134/s1070363209040367
• 作为产物：
  描述：

  1-甲基-5-甲基吡唑-4-甲醛 在 sodium tetrahydroborate 、 苄基三乙基氯化铵 作用下， 以 水 为溶剂， 反应 5.0h， 以85%的产率得到1,5-Dimethyl-4-hydroxymethylpyrazole
  参考文献：
  名称：

  13C NMR spectra of 4-hydroxymethylpyrazoles and their chemical behavior at heating

  摘要：

  It was established that in the C-13 NMR spectra of 4-hydroxymethylpyrazoles the carbon atom of hydroxymethyl group of 1,3,5-trimethyl-4-hydroxymethylpyrazole is deshielded by 6.28-6.78 ppm compared to 1-methyl-4-hydroxymethyl-, 1,3-dimethyl-4-hydroxymethyl- and 1,5-dimethyl-4-hydroxymethylpyrazoles. It is assumed that this difference is related to their dissimilar behavior at heating.

  DOI：

  10.1134/s1070363210050245

文献信息

• Heterocyclic fused 2,5-dihydrothiophene S,S-dioxides as precursors to heterocyclic o-quinodimethanes
  作者：Lynne M. Chaloner、Andrew P.A. Crew、Paul M. O'Neill、Richard C. Storr、Michael Yelland

  DOI：10.1016/s0040-4020(01)80480-4

  日期：1992.1

  5-bischloromethylthiophene-2-carboxylate by reaction with sodium sulfide and oxidation. Pyrazole fused analogues 15 and 16 (R = Me and COPh) were prepared from 3-phenylsulfonyl-2,5-dihydrothiophene S,S-dioxide by cycloaddition of diazomethane, base induced aromatisation and N-substitution of the sulfone 14. Reaction of 3-acetyl-4-phenylthio-2,5-dihydrothiophene S,S-dioxide with hydrazine and interception of

  2,5-Dihydrothiophene 5,5-dioxides 8 and 6 have been obtained by interception of flash-pyrolytically produced 2,3-dihydro-2,3-bis(methylene)thiophene with sulfur dioxide and from methyl 4,5-bischloromethylthiophene-2-carboxylate by reaction with sodium sulfide and oxidation. Pyrazole fused analogues 15 and 16 (R = Me and COPh) were prepared from 3-phenylsulfonyl-2,5-dihydrothiophene S,S-dioxide by cycloaddition
• Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands
  申请人：Bettati Michela

  公开号：US20060040940A1

  公开（公告）日：2006-02-23

  The present invention provides a pharmaceutical composition providing a compound of formula I or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable excipient: (I), in which: X and Y independently represent CH or N, with the proviso that if X is CH then Y is also CH; R 1 represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, —OR a , —SR a , —SOR a , —SO 2 R a , —SO 2 NR a R b , —NR a R b , —NR a COR b , —NR a CO 2 R b , —COR a , —CO 2 R a , —CONR a R b or CR a ═NOR b ; R a and R b independently represent hydrogen, hydrocarbon or a heterocyclic group; V and W are independently selected from H, halogen, C 11-6 alkyl, OH and C -1-6 alkoxy; Z represents H, halogen, CN, NO 2 , CF 3 , OCF 3 , CF 2 H, SCF 3 , R 2 , OR 3 , SR 3 , (CH 2 )pN(R 3 ) 2 , O(CH 2 )pN(R 3 ) 2 , SO 2 R 2 , SO 2 N(R 3 ) 2 , COR 4 , CO 2 R 3 , CON(R 3 ) 2 , NHCOR 4 , NR 1 (CH 2 ) n heteroaryl or O(CH 2 ) n heteroaryl the heteroaryl is optionally substituted by one, two or three groups chosen from C 1-6 alkyl, benzyl, (CH 2 )pN(R 3 ) 2 , halogen and CF 3 , R 1 is C 1-6 alkyl, where n is 1 or 2 and p is 0, 1 or 2; with the proviso that at least one of V, W and Z is other than H; R 2 represents C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkylC 1-4 alkyl, C 2-6 alkenyl, C 2-6 alkynyl or heteroaryl, any of which may bear a substituent selected from halogen, CN, NO 2 , CF 3 , OCF 3 , CF 2 H, SCF 3 , OH, C 1-4 alkoxy, C 1-4 alkoxycarbonyl, amino, C 1-4 alkylamino, or di(C 1-4 alkyl)amino; R 3 represents H or R 2 ; or two R 3 groups bonded to the same nitrogen atom may complete a 5-7 membered nonaromatic heterocyclic ring; and R 4 represents R 3 or heteroaryl; the compounds are ligands for GABA-A receptors containing the alpha 5 subtype and thus are useful for enhancing cognition in individuals suffering from conditions such as Alzheimer's Disease.

  本发明提供了一种制药组合物，其中包含式I的化合物或其药学上可接受的盐，以及药学上可接受的载体：（I），其中：X和Y独立地表示CH或N，但如果X是CH，则Y也是CH；R1表示氢、碳氢化合物、杂环基、卤素、氰基、三氟甲基、硝基、—ORa、—SRa、—SORa、—SO2Ra、—SO2NRaRb、—NRaRb、—NRaCORb、—NRaCO2Rb、—CORa、—CO2Ra、—CONRaRb或CRa═NORb；Ra和Rb独立地表示氢、碳氢化合物或杂环基；V和W独立地选自H、卤素、C11-6烷基、OH和C-1-6烷氧基；Z表示H、卤素、CN、NO2、CF3、OCF3、CF2H、SCF3、R2、OR3、SR3、（CH2）pN（R3）2、O（CH2）pN（R3）2、SO2R2、SO2N（R3）2、COR4、CO2R3、CON（R3）2、NHCOR4、NR1（CH2）n杂环基或O（CH2）n杂环基，其中杂环基可选地被来自C1-6烷基、苯甲基、（CH2）pN（R3）2、卤素和CF3的一个、两个或三个基团取代，R1是C1-6烷基，其中n为1或2，p为0、1或2；但要求V、W和Z中至少有一个不是H；R2表示C1-6烷基、C3-6环烷基、C3-6环烷基C1-4烷基、C2-6烯基、C2-6炔基或杂环基，其中任何一种可以携带来自卤素、CN、NO2、CF3、OCF3、CF2H、SCF3、OH、C1-4烷氧基、C1-4烷氧羰基、氨基、C1-4烷基氨基或二（C1-4烷基）氨基的取代基；R3表示H或R2；或者两个结合到同一氮原子上的R3基团可以形成一个5-7成员非芳香杂环环；R4表示R3或杂环基；这些化合物是GABA-A受体的配体，包含α5亚型，因此对于患有阿尔茨海默病等疾病的个体，有助于增强认知能力。
• PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS
  申请人：Attardo Giorgio

  公开号：US20100298336A1

  公开（公告）日：2010-11-25

  The present invention features compounds having the Formula (Ia) and (Ib) (e.g., a compound of any of Formulas ((Ia-2)-(Ia-21)), including other tautomers, stereoisomers, E/Z stereoisomers, prodrugs, pharmaceutically acceptable salts, and compositions thereof. The invention also features methods for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient by administering an effective amount of a compound of Formula (Ia) or (Ib). The invention also features a method for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient that includes administering to a patient in need thereof an effective amount of a compound of Formula (IIa) or (IIb) (e.g., a compound of any of Formulas ((IIa-2)-(IIa-6)). The compounds described herein (e.g., a compound of Formulas (Ia), (Ib), (IIa), or (IIb)) can also be used as anticonvulsants.

  本发明涉及化合物的公式（Ia）和（Ib）（例如，包括任何公式（（Ia-2）-（Ia-21））的化合物，包括其他互变异构体，立体异构体，E / Z立体异构体，前药，药物可接受的盐和其组合物。本发明还涉及通过给予公式（Ia）或（Ib）的化合物的有效量来治疗或预防病人的疼痛（例如，神经病理性疼痛），炎症或癫痫的方法。本发明还涉及一种治疗或预防病人的疼痛（例如，神经病理性疼痛），炎症或癫痫的方法，包括向需要该治疗的病人给予公式（IIa）或（IIb）的化合物的有效量（例如，包括任何公式（（IIa-2）-（IIa-6））的化合物）。本文描述的化合物（例如，公式（Ia），（Ib），（IIa）或（IIb）的化合物）还可用作抗癫痫药。
• 3-PYRROLIDINYLTHIO-CARBAPENEM DERIVATIVES AND THEIR ANTIMICROBAL ACTIVITY
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0722447A1

  公开（公告）日：1996-07-24
• DERIVES D'IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONE ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：Aventis Pharma S.A.

  公开号：EP0752992B1

  公开（公告）日：2001-05-30